BioSpace News Archive

In a patent infringement lawsuit filed against Eli Lilly, Teva Pharmaceuticals won three and lost six patents. The patent lawsuit was over Teva’s Ajovy (fremanezumab-vfrm) to prevent migraines.

Eli Lilly has announced the success of its clinical trial on lebrikizumab as a treatment for people diagnosed with moderate to severe atopic dermatitis.

As the COVID-19 pandemic continues with surges in the U.S. in unvaccinated people, biopharma companies are still working on new vaccines and therapies against the disease.

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, announced that Michael J. Parini has succeeded Theresa Heggie as Chief Executive Officer.

Woundtech, a leading wound management company serving Medicare Advantage health plans and at-risk senior care provider groups, announced that Brian Wise has been named as its Chief Executive Officer.

A complete workflow developed by Promega Corporation enables wastewater testing laboratories, including public health organizations, to quickly assess the health of entire communities from a single sample.

Enanta Pharmaceuticals, Inc., today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-721, a novel, oral hepatitis B virus (HBV) RNA destabilizer being developed for use in an all-oral combination regimen for chronic HBV patients.

Rocket Pharmaceuticals, Inc. today announces that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Phase 1 clinical trial of RP-A501 for the treatment of Danon Disease, allowing patient enrollment to resume.

Virbac announces the breakthrough drug STELFONTA ® (tigilanol tiglate injection) that has been approved by the U.S. Food and Drug Administration (FDA) as a non-surgical alternative for treating canine mast cell tumors in dogs, is now available in veterinary clinics throughout the United States .

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in research-driven development and manufacturing of cannabis API and finished dose products today announced its financial results for the three and six months ended June 30, 2021, a period of ongoing progress in establishing itself as an international pharmaceutical company specializing in cannabis.